Ko Jisook, Wang Jing, Chung Misook L, Sharma Kumar
School of Nursing, University of Texas Health San Antonio, San Antonio, TX, United States.
College of Nursing, Florida State University, Tallahassee, FL, United States.
JMIR Res Protoc. 2023 Feb 13;12:e39058. doi: 10.2196/39058.
Excessive dietary sodium intake is an independent risk factor for hypertension and cardiovascular disease (CVD). Despite the large body of evidence concerning the effects of dietary interventions on blood pressure (BP) and CVD outcomes, trials have often reported low adherence to decreased sodium intake, likely due in part to heterogeneous BP responses. To address the challenges, recent clinical findings suggested a precise and personalized dietary approach that seeks to deliver more preventive and practical dietary advice than the "one-size-fits-all" guidelines and weighs the personal risk of developing specific diseases.
The purpose of this pilot randomized controlled trial was to test the feasibility and preliminary efficacy of integrating the use of mobile technology and metabolomics with a low-sodium diet intervention in patients with hypertension to develop personalized low-sodium diet programs. Additionally, the study will examine the associations of urine metabolites with urinary sodium levels and BP control based on the hypothesis that targeted urine metabolites. In this report, we describe the design and protocol of the pilot trial.
A total of 40 patients with hypertension will be randomly assigned to either a 8-week low-sodium diet group (n=20) or a standard care group (n=20). Each week, intervention participants went through individual sessions with an interventionist via videoconferencing to discuss low-sodium diet regimens, patients' food choices, and BP tracks on mobile apps. The control group followed their usual care for hypertension management. All participants in both groups monitored diet and BP using mobile apps for 8 weeks. A 24-hour urinary sodium excretion for the estimation of dietary sodium intake, systolic, and diastolic BPs were measured at the baseline and at 8 weeks. The primary outcomes of this study include the feasibility of conducting a randomized controlled trial (RCT) by reporting recruitment, retention, and completion statistics. The preliminary effects of intervention will be tested by a generalized estimating equation model.
This pilot RCT study was approved by the institutional review board at the University of Texas Health San Antonio in January 2021. The first participant was enrolled in April 2021, and currently, 26 participants were enrolled. All data collection is expected to conclude by March 2023, with data analysis and study results ready for reporting by December 2023. Findings from this pilot RCT will further guide the team in planning a future large-scale study.
The findings of this proposed study will establish a comprehensive knowledge base for future research and development of personalized dietary interventions to promote adherence to dietary strategies and self-management of chronic disease using the Precision Health approach for millions of Americans who are struggling with uncontrolled hypertension.
ClinicalTrials.gov NCT04764253; https://clinicaltrials.gov/ct2/show/NCT04764253.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/39058.
过量的膳食钠摄入是高血压和心血管疾病(CVD)的独立危险因素。尽管有大量关于饮食干预对血压(BP)和CVD结局影响的证据,但试验经常报告钠摄入量降低的依从性较低,这可能部分归因于血压反应的异质性。为应对这些挑战,最近的临床研究结果提出了一种精确且个性化的饮食方法,该方法旨在提供比“一刀切”指南更具预防性和实用性的饮食建议,并权衡患特定疾病的个人风险。
这项初步随机对照试验的目的是测试将移动技术和代谢组学与低钠饮食干预相结合,为高血压患者制定个性化低钠饮食方案的可行性和初步疗效。此外,该研究将基于靶向尿液代谢物的假设,研究尿液代谢物与尿钠水平及血压控制之间的关联。在本报告中,我们描述了该初步试验的设计和方案。
总共40名高血压患者将被随机分配到8周低钠饮食组(n = 20)或标准护理组(n = 20)。每周,干预组参与者通过视频会议与干预人员进行单独会面,讨论低钠饮食方案、患者的食物选择以及移动应用程序上的血压轨迹。对照组遵循其常规的高血压管理护理。两组的所有参与者使用移动应用程序监测饮食和血压8周。在基线和8周时测量24小时尿钠排泄量以估计膳食钠摄入量、收缩压和舒张压。本研究的主要结局包括通过报告招募、保留和完成统计数据来评估进行随机对照试验(RCT)的可行性。干预的初步效果将通过广义估计方程模型进行测试。
这项初步RCT研究于2021年1月获得德克萨斯大学圣安东尼奥健康科学中心机构审查委员会的批准。第一名参与者于2021年4月入组,目前已招募了26名参与者。所有数据收集预计于2023年3月结束,数据分析和研究结果准备于2023年12月报告。这项初步RCT的结果将进一步指导研究团队规划未来的大规模研究。
这项拟议研究的结果将为未来个性化饮食干预的研发建立一个全面的知识库,以促进数百万患有未控制高血压的美国人采用精准健康方法坚持饮食策略和慢性病自我管理。
ClinicalTrials.gov NCT04764253;https://clinicaltrials.gov/ct2/show/NCT04764253。
国际注册报告识别码(IRRID):DERR1-10.2196/39058。